This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

20 Jul 2011

Valeant and Sanofi Sign Distribution Agreement for Zuacta Cream

Valeant Pharmaceuticals is acquiring the Canadian marketing and distribution rights to the Zuacta cream for treating knee osteoarthritis under a marketing agreement with Sanofi.

Valeant Pharmaceuticals International, Inc. announced yesterday that its subsidiary, Valeant International (Barbados) SRL, has signed an agreement with Sanofi-aventis Canada Inc. for the Canadian marketing and distribution rights to Zuacta. Zuacta is a topical cream of zucapsaicin, which is indicated to be used in conjunction with oral COX-2 inhibitors or NSAIDs for the relief of severe pain in adult patients with osteoarthritis of the knee.


Under the terms of the distribution agreement, Sanofi-aventis will receive from Valeant consideration that includes an initial payment payable on the delivery of the first shipment of product and milestone payments based on net sales.


"Zuacta will be another strong addition to our product portfolio i

Related News